S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
S&P 500   3,116.39 (-0.38%)
DOW   26,957.59 (-0.46%)
QQQ   216.48 (+0.52%)
AAPL   292.65 (+1.59%)
FB   197.20 (+0.22%)
MSFT   170.17 (+1.25%)
GOOGL   1,390.47 (+0.30%)
AMZN   1,979.59 (+0.35%)
CGC   19.82 (+1.02%)
NVDA   267.65 (+2.14%)
BABA   208.74 (+1.52%)
MU   52.37 (+0.52%)
GE   10.95 (-3.27%)
TSLA   778.80 (-2.64%)
AMD   47.49 (-0.17%)
T   37.10 (-0.67%)
ACB   1.51 (+0.00%)
F   7.21 (-0.28%)
NFLX   379.24 (+5.32%)
PRI   120.14 (-1.05%)
BAC   30.63 (-1.45%)
DIS   123.36 (-3.77%)
GILD   74.70 (+6.56%)
Log in

OTCMKTS:ELOX - Eloxx Pharmaceuticals Stock Price, Forecast & News

$3.54
-0.05 (-1.39 %)
(As of 02/26/2020 04:00 PM ET)
Today's Range
$3.46
Now: $3.54
$3.73
50-Day Range
$3.54
MA: $4.61
$7.77
52-Week Range
$2.87
Now: $3.54
$14.74
Volume75,200 shs
Average Volume192,787 shs
Market Capitalization$141.61 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:ELOX
CUSIPN/A
CIKN/A
Phone858-909-0749

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$141.61 million
Next Earnings DateN/A
OptionableNot Optionable

Receive ELOX News and Ratings via Email

Sign-up to receive the latest news and ratings for ELOX and its competitors with MarketBeat's FREE daily newsletter.


Eloxx Pharmaceuticals (OTCMKTS:ELOX) Frequently Asked Questions

What is Eloxx Pharmaceuticals' stock symbol?

Eloxx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ELOX."

How were Eloxx Pharmaceuticals' earnings last quarter?

Eloxx Pharmaceuticals (OTCMKTS:ELOX) released its earnings results on Tuesday, November, 5th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.07. View Eloxx Pharmaceuticals' Earnings History.

What price target have analysts set for ELOX?

3 brokerages have issued 12-month price targets for Eloxx Pharmaceuticals' shares. Their forecasts range from $10.00 to $17.00. On average, they anticipate Eloxx Pharmaceuticals' share price to reach $13.67 in the next twelve months. This suggests a possible upside of 286.1% from the stock's current price. View Analyst Price Targets for Eloxx Pharmaceuticals.

What is the consensus analysts' recommendation for Eloxx Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eloxx Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eloxx Pharmaceuticals.

Has Eloxx Pharmaceuticals been receiving favorable news coverage?

Media stories about ELOX stock have trended somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eloxx Pharmaceuticals earned a media sentiment score of 2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Eloxx Pharmaceuticals.

Who are some of Eloxx Pharmaceuticals' key competitors?

What other stocks do shareholders of Eloxx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Eloxx Pharmaceuticals investors own include Novavax (NVAX), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Boeing (BA), Canopy Growth (CGC), Arbutus Biopharma (ABUS), Aclaris Therapeutics (ACRS), Aptose Biosciences (APTO) and Ardelyx (ARDX).

Who are Eloxx Pharmaceuticals' key executives?

Eloxx Pharmaceuticals' management team includes the folowing people:
  • Mr. Robert E. Ward, Chairman & CEO (Age 60)
  • Dr. Silvia Noiman, Founder & Director (Age 62)
  • Mr. Gregory L. Weaver CPA, M.B.A., Chief Financial Officer (Age 62)
  • Dr. Pedro Huertas, Chief Medical Officer (Age 63)
  • Dr. Colin Scott M.B., Ch.B., Medical Director (Age 66)

Who are Eloxx Pharmaceuticals' major shareholders?

Eloxx Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Menora Mivtachim Holdings LTD. (5.24%), State Street Corp (1.05%), Geode Capital Management LLC (0.87%), Meitav Dash Investments Ltd. (0.85%), Renaissance Technologies LLC (0.34%) and Bank of New York Mellon Corp (0.17%). Company insiders that own Eloxx Pharmaceuticals stock include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Institutional Ownership Trends for Eloxx Pharmaceuticals.

Which institutional investors are selling Eloxx Pharmaceuticals stock?

ELOX stock was sold by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Menora Mivtachim Holdings LTD. and Citigroup Inc.. View Insider Buying and Selling for Eloxx Pharmaceuticals.

Which institutional investors are buying Eloxx Pharmaceuticals stock?

ELOX stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Geode Capital Management LLC, State Street Corp, UBS Group AG, Barclays PLC, Bank of America Corp DE and Bank of New York Mellon Corp. Company insiders that have bought Eloxx Pharmaceuticals stock in the last two years include Gilad Shabtai, Gregory L Weaver, Pontifax Management 4 GP (20, Robert Ward, Tomer Kariv and Zafrira Avnur. View Insider Buying and Selling for Eloxx Pharmaceuticals.

How do I buy shares of Eloxx Pharmaceuticals?

Shares of ELOX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Eloxx Pharmaceuticals' stock price today?

One share of ELOX stock can currently be purchased for approximately $3.54.

How big of a company is Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals has a market capitalization of $141.61 million. View Additional Information About Eloxx Pharmaceuticals.

What is Eloxx Pharmaceuticals' official website?

The official website for Eloxx Pharmaceuticals is http://www.eloxxpharma.com/.

How can I contact Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals' mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The company can be reached via phone at 858-909-0749 or via email at [email protected]


MarketBeat Community Rating for Eloxx Pharmaceuticals (OTCMKTS ELOX)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  234 (Vote Underperform)
Total Votes:  407
MarketBeat's community ratings are surveys of what our community members think about Eloxx Pharmaceuticals and other stocks. Vote "Outperform" if you believe ELOX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ELOX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/26/2020 by MarketBeat.com Staff

Featured Article: Derivative

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel